Enhanced Buys $670M of Revenue Because It Couldn't Grow $3M of It
A telehealth start-up with $12.1M of cash just agreed to acquire a 6,000-event German concert promoter — and asked investors to wait until January to see the marketing machine turn on.
ENHA · Earnings Call · 2026-11-12
A quarter of preparation, or a quarter of retreat
Enhanced Group's third quarter as a public company was, by its own CFO's framing, deliberately uneventful. “The third quarter was our first full quarter as a public company, and in many ways, a quarter of preparation.” — Sid Banthiya, Chief Financial Officer · 2026-11-12 That is a polite way of describing a 81% sequential revenue decline: $3.3M in Q3 against $17.7M in Q2, the latter inflated by the inaugural Enhanced Games in May. The consumer business — Live Enhanced, the telehealth arm — generated about $1.1M of gross revenue on $1.5M of performance spend, up from roughly $0.4M in Q2 on the same spend. Marketing efficiency tripled; absolute revenue stayed small. The bet management is asking investors to underwrite is that the small number is a choice, not a ceiling. “In Q3, we have deliberately held back on a major increase in paid marketing because we wanted to focus instead on strengthening and further building out this strong foundation.” — Maximilian Martin, Chief Executive Officer · 2026-11-12 Read the keywords from this call and you see where the money went instead: Enhanced OS dominated the quarter, alongside peptides (six new ones, including BPC-157 and TB-500, now ~20 prescription treatments), hormone optimization, and a promised brand redesign because, in the CEO's own words, the current site is “very dark, it is very male-led, very science-y, very tech bro-y.” — Maximilian Martin, Chief Executive Officer · 2026-11-12 That is a rare admission for a company whose entire brand equity was built on athletes. It is also the most honest sentence on the call.The pivot: buying scale is faster than building it
One week before reporting, Enhanced announced it will acquire a majority stake in DEAG, a German live-entertainment group that stages more than 6,000 events, sells more than 12 million tickets annually, and owns myticket, which Max calls the third-largest ticketing business in Europe. Consideration is entirely in stock, at roughly 5.3x projected lease-adjusted EBITDA — a claimed 63% discount to listed peers. The 2027 pro-forma guide is the headline: approximately $670M of combined revenue and about $26M of positive adjusted EBITDA, versus a standalone Q3 adjusted EBITDA loss of $8.8M. That is a transformation of the P&L executed with paper, not operations. And the CFO was refreshingly blunt that the case rests on nothing but the assets: “we didn't include any synergies in the forecast that we made, either on the cost side or on the top line side.” — Sid Banthiya, Chief Financial Officer · 2026-11-12 Which is exactly the right question to ask. The synergy story is real but slow — cross-selling supplements to festival-goers, shared sponsorship, using myticket to ticket the Games. The CEO conceded the top-line version takes years. The cost version is faster, and also smaller. The second leg is the sports business. Next year's Enhanced Games are planned for Q4 with a ~$20M budget, down from a six-hour event to about three, with three new revenue lines on top of sponsorship: media rights sales, ticketing, and host city economic development support. Management expects the sports segment to break even in 2027. Given that the first Games cost $52M in Q2 event spend and produced a $42.7M adjusted EBITDA loss, break-even is a genuine step change — but it is also entirely dependent on sponsorship holding while three new lines materialise in a single quarter.Enhanced OS lands on a crowded agent wave
The product itself is more interesting than the promotional language around it. Enhanced OS pulls electronic medical records, 100-plus biomarkers, and wearable data into a $199 annual membership that recommends a personalised protocol — supplements now, prescriptions by January. In the global keyword set, Personal AI agents is a rising theme this quarter, and Enhanced is positioning squarely inside it: a consumer health agent that owns the wallet via in-app marketplace purchases. The competitive set, though, is loud. Across the recent reporter cohort, GLP-1 and weight-management language appeared at Hims, LifeMD, Dario, and Zeal — including oral GLP-1 ambitions — with far larger marketing budgets and existing subscriber bases. Enhanced's differentiator is medical oversight and the athlete-derived protocol IP, which is thin moat material. A 38-year-old browsing a redesigned, women-friendly homepage is not obviously going to choose the company that ran a steroid-adjacent sporting event over the one already in her Instagram feed. There is also a subtle environmental tell. Max's macro thesis is explicitly the flip side of AI — people paying for in-person experience as digital content gets cheap. Look at the global tape and the AI infrastructure complex is being sold hard over the last 30 days, with data-center and high-bandwidth-memory baskets deeply negative. Enhanced is, in effect, a leveraged short on that trade expressed through live music and a supplement app. That is a real thesis. It is also a thesis that requires consumers to keep spending on $200 festival tickets.What the balance sheet actually says
The gap between narrative and financials is widest in the liquidity discussion. Enhanced ended Q3 with $12.1M in cash, against a quarterly operating loss of $62M and negative free cash flow of $44M. Management's bridge to ~$47M of liquidity leans on $10M of Rezolve shares unlocking in December, a $10M ZOOP consideration, and a fresh private placement of $15M. That $15M is worth flagging. In prepared remarks, the CEO described the DEAG transaction as coming “together with a concurrent $50 million private placement” — Maximilian Martin, Chief Executive Officer · 2026-11-12 — then three paragraphs later referred to "the concurrent $15 million financing." The $50M PIPE was the Q3 raise; the new money is $15M. It is a slip, but on a call where the entire equity story is "trust us on the numbers," it is the kind of slip that gets noticed. There is also a quiet dependency worth naming: $3.1M of the quarter's SG&A was non-cash Rumble marketing expense, tied to a partnership with the video platform that reported its own quarter days earlier. Enhanced is drawing on marketing credits rather than cash — which flatters the cost base but does not build a customer base.The pressure point
The call closes with something you rarely hear: an unprompted acknowledgement of the stock.Fair enough. But the honest read of this quarter is that Enhanced has traded organic growth ambition for inorganic scale. The paid marketing freeze is defensible only if Enhanced OS converts in January; the DEAG deal is defensible only if 2027 pro-forma numbers hold without synergies; and both are defensible only if the $47M liquidity bridge closes cleanly. Three conditional statements stacked on a company that, one quarter ago, booked $17.7M of revenue because it ran a sporting event. The next real datapoint is not the DEAG close. It is January, when the marketing dollars are supposed to turn on and the protocol engine meets a customer who has other options.I know that our share price performance can be very frustrating for some of our investors. The only thing that we can do as management, the company, our athletes, and everyone else who's involved is to properly hunker down and work on operating and getting results done.